ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 224 filers reported holding ACADIA PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.68 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,633,412 | -14.3% | 174,348 | -1.5% | 0.27% | -8.3% |
| Q2 2023 | $4,240,635 | +126827.1% | 177,062 | -0.3% | 0.29% | +21.8% |
| Q1 2023 | $3,341 | +19.4% | 177,523 | +1.0% | 0.24% | +24.0% |
| Q4 2022 | $2,799 | -99.9% | 175,841 | -1.1% | 0.19% | -13.1% |
| Q3 2022 | $2,910,000 | +20.1% | 177,852 | +3.4% | 0.22% | +26.3% |
| Q2 2022 | $2,422,000 | -40.7% | 171,922 | +2.0% | 0.18% | -33.2% |
| Q1 2022 | $4,084,000 | +4.0% | 168,621 | +0.2% | 0.26% | +9.6% |
| Q4 2021 | $3,928,000 | +40.8% | 168,276 | +0.2% | 0.24% | +30.6% |
| Q3 2021 | $2,790,000 | -31.1% | 167,953 | +1.2% | 0.18% | -29.6% |
| Q2 2021 | $4,048,000 | -2.4% | 165,965 | +3.2% | 0.26% | -8.8% |
| Q1 2021 | $4,149,000 | +46.3% | 160,818 | +203.2% | 0.28% | +42.5% |
| Q4 2020 | $2,836,000 | +125.3% | 53,046 | +73.8% | 0.20% | +98.0% |
| Q3 2020 | $1,259,000 | – | 30,526 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |